Form to function: current and future roles for atherosclerosis imaging in drug development
Alistair C. Lindsay,Robin P. Choudhury
DOI: https://doi.org/10.1038/nrd2588
IF: 112.288
2008-05-16
Nature Reviews Drug Discovery
Abstract:Key PointsThe recent failure of novel anti-atherosclerotic therapies in Phase III clinical trials has emphasized the pressing need for robust imaging markers that can reliably assist in the development of drugs for the treatment of atherosclerosis.Conventional methods of imaging atherosclerosis are able to provide quantitative and morphological data, and to date, have principally been used to assess the efficacy of cholesterol-lowering agents.In this article we compare the main imaging modalities used to image atherosclerosis in the clinical trial setting so far, namely quantitative coronary angiography (QCA), carotid intima-media thickness (CIMT), magnetic resonance imaging (MRI), computed tomography (CT) and intravascular ultrasound (IVUS). The ability of these imaging modalities to predict clinical outcomes for a given sample size, and the regulatory considerations pertaining to their use, are also discussed.However, these methods are likely to be inadequate to assess an emerging generation of therapies that modify plaque biology directly. For example, squalene synthase inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitors, and chemokine (C-C motif) receptor 2 (CCR2) antagonists.We outline how emerging molecular and cellular imaging techniques offer the possibility to quantify changes in biological function at the level of the plaque, even without gross structural change. In this regard, two imaging modalities are discussed in detail: MRI and positron-emission tomography (PET).Currently, no single ideal imaging modality exists. In the future, the careful application of imaging biomarkers will be necessary to ensure that new anti-atherosclerosis therapies are evaluated in the most efficient manner possible.
pharmacology & pharmacy,biotechnology & applied microbiology